Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
AgonOx, Inc.
Essen Biotech
National Cancer Institute (NCI)
NeogenTC
Roger Williams Medical Center